Cargando…

The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials

BACKGROUND: In recent years, with the enormous advances in the field of cardiac intervention technology, the survival rate of patients with acute myocardial infarction (AMI) has been improved significantly. However, the risk of arrhythmias and heart failure remains very high in AMI patients for long...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuqin, Wu, Jiani, Guo, Shuwen, Lin, Wangou, Zhang, Binyue, Chen, Xi, Mo, Hanrong, Zhan, Tianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494254/
https://www.ncbi.nlm.nih.gov/pubmed/31008964
http://dx.doi.org/10.1097/MD.0000000000015256
_version_ 1783415240196620288
author Zhang, Yuqin
Wu, Jiani
Guo, Shuwen
Lin, Wangou
Zhang, Binyue
Chen, Xi
Mo, Hanrong
Zhan, Tianwei
author_facet Zhang, Yuqin
Wu, Jiani
Guo, Shuwen
Lin, Wangou
Zhang, Binyue
Chen, Xi
Mo, Hanrong
Zhan, Tianwei
author_sort Zhang, Yuqin
collection PubMed
description BACKGROUND: In recent years, with the enormous advances in the field of cardiac intervention technology, the survival rate of patients with acute myocardial infarction (AMI) has been improved significantly. However, the risk of arrhythmias and heart failure remains very high in AMI patients for long-term prognosis. Chinese herbal medicine (CHM) is more and more used in the treatment of AMI because of its good curative effect and less side effects. The target of this research is to analyze the efficacy and safety of Astragalus (Huangqi) preparation in the treatment of AMI by meta-analysis and also to provide a better evidence for clinical practice. METHODS: Seven databases will be searched in this study: The Cochrane Library, PubMed, Web of Science, the Chinese National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (CSJD), the Chinese Biomedical Literature Database (CBM), and Wanfang DATA. The following search terms will be used: (Huangqi OR Huang Qi OR Astragalus OR radix astragali) AND (acute myocardial infaction OR myocardial infaction OR AMI) AND (randomized controlled trial OR RCT OR randomized). No language limitations and the searches will be conducted up to March, 2019. Inclusion criteria: randomized controlled trial (RCT) of Astragalus (Huangqi) preparation in patients with AMI. Main outcome measures will be left ventricular end systolic volume (LVESV), left ventricular end diastolic volume (LVEDV), left ventricular ejection fraction (LVEF), left ventricular mass index (LVMI), recanalization rate, mortality rate, incidence of reperfusion arrhythmias, postinfarction angina pectoris, and re-infarction rate. Secondary outcome indicators were the incidence of adverse reactions and the effective rate of traditional Chinese medicine (TCM) treatment. Two independent reviewers will filter the literature and extract data which based to the Cochrane manual. The relevant data, including bias risk assessment, data synthesis, subgroup analysis, meta-analysis, and final meta-analysis, will be analyzed with RevMan 5.3 software. The funnel diagram will be used to evaluate the reported deviation, and the Egger test will be used to evaluate the symmetry of the funnel graph. RESULTS: This systematic review study will provide a clear basis for evaluating the efficacy and safety of Astragalus (Huangqi) preparation with the treatment of AMI. CONCLUSION: This study will provide an up-to-date evidence for evaluating the efficacy and safety of Astragalus (Huangqi) preparation. PROSPERO REGISTRATION NUMBER: CRD42019124843.
format Online
Article
Text
id pubmed-6494254
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-64942542019-05-29 The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials Zhang, Yuqin Wu, Jiani Guo, Shuwen Lin, Wangou Zhang, Binyue Chen, Xi Mo, Hanrong Zhan, Tianwei Medicine (Baltimore) Research Article BACKGROUND: In recent years, with the enormous advances in the field of cardiac intervention technology, the survival rate of patients with acute myocardial infarction (AMI) has been improved significantly. However, the risk of arrhythmias and heart failure remains very high in AMI patients for long-term prognosis. Chinese herbal medicine (CHM) is more and more used in the treatment of AMI because of its good curative effect and less side effects. The target of this research is to analyze the efficacy and safety of Astragalus (Huangqi) preparation in the treatment of AMI by meta-analysis and also to provide a better evidence for clinical practice. METHODS: Seven databases will be searched in this study: The Cochrane Library, PubMed, Web of Science, the Chinese National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (CSJD), the Chinese Biomedical Literature Database (CBM), and Wanfang DATA. The following search terms will be used: (Huangqi OR Huang Qi OR Astragalus OR radix astragali) AND (acute myocardial infaction OR myocardial infaction OR AMI) AND (randomized controlled trial OR RCT OR randomized). No language limitations and the searches will be conducted up to March, 2019. Inclusion criteria: randomized controlled trial (RCT) of Astragalus (Huangqi) preparation in patients with AMI. Main outcome measures will be left ventricular end systolic volume (LVESV), left ventricular end diastolic volume (LVEDV), left ventricular ejection fraction (LVEF), left ventricular mass index (LVMI), recanalization rate, mortality rate, incidence of reperfusion arrhythmias, postinfarction angina pectoris, and re-infarction rate. Secondary outcome indicators were the incidence of adverse reactions and the effective rate of traditional Chinese medicine (TCM) treatment. Two independent reviewers will filter the literature and extract data which based to the Cochrane manual. The relevant data, including bias risk assessment, data synthesis, subgroup analysis, meta-analysis, and final meta-analysis, will be analyzed with RevMan 5.3 software. The funnel diagram will be used to evaluate the reported deviation, and the Egger test will be used to evaluate the symmetry of the funnel graph. RESULTS: This systematic review study will provide a clear basis for evaluating the efficacy and safety of Astragalus (Huangqi) preparation with the treatment of AMI. CONCLUSION: This study will provide an up-to-date evidence for evaluating the efficacy and safety of Astragalus (Huangqi) preparation. PROSPERO REGISTRATION NUMBER: CRD42019124843. Wolters Kluwer Health 2019-04-19 /pmc/articles/PMC6494254/ /pubmed/31008964 http://dx.doi.org/10.1097/MD.0000000000015256 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Zhang, Yuqin
Wu, Jiani
Guo, Shuwen
Lin, Wangou
Zhang, Binyue
Chen, Xi
Mo, Hanrong
Zhan, Tianwei
The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials
title The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials
title_full The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials
title_fullStr The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials
title_full_unstemmed The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials
title_short The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials
title_sort clinical efficacy and safety of the chinese herbal medicine astragalus (huangqi) preparation for the treatment of acute myocardial infarction: a systematic review of randomized controlled trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494254/
https://www.ncbi.nlm.nih.gov/pubmed/31008964
http://dx.doi.org/10.1097/MD.0000000000015256
work_keys_str_mv AT zhangyuqin theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT wujiani theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT guoshuwen theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT linwangou theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT zhangbinyue theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT chenxi theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT mohanrong theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT zhantianwei theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT zhangyuqin clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT wujiani clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT guoshuwen clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT linwangou clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT zhangbinyue clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT chenxi clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT mohanrong clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials
AT zhantianwei clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials